264 related articles for article (PubMed ID: 30262570)
1. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.
Greiner J; Schrappe M; Claviez A; Zimmermann M; Niemeyer C; Kolb R; Eberl W; Berthold F; Bergsträsser E; Gnekow A; Lassay E; Vorwerk P; Lauten M; Sauerbrey A; Rischewski J; Beilken A; Henze G; Korte W; Möricke A;
Haematologica; 2019 Apr; 104(4):756-765. PubMed ID: 30262570
[TBL] [Abstract][Full Text] [Related]
2. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
[TBL] [Abstract][Full Text] [Related]
3. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis of the effectiveness of primary thromboprophylaxis in acute lymphoblastic leukemia during early-phase therapy including asparaginase or its prolonged form.
Hu Z; Persaud Y; Ahuja S
Crit Rev Oncol Hematol; 2024 May; 197():104347. PubMed ID: 38583546
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
Kearon C; Ginsberg JS; Julian JA; Douketis J; Solymoss S; Ockelford P; Jackson S; Turpie AG; MacKinnon B; Hirsh J; Gent M;
JAMA; 2006 Aug; 296(8):935-42. PubMed ID: 16926353
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
Merli G; Spiro TE; Olsson CG; Abildgaard U; Davidson BL; Eldor A; Elias D; Grigg A; Musset D; Rodgers GM; Trowbridge AA; Yusen RD; Zawilska K;
Ann Intern Med; 2001 Feb; 134(3):191-202. PubMed ID: 11177331
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
Petersen JL; Mahaffey KW; Hasselblad V; Antman EM; Cohen M; Goodman SG; Langer A; Blazing MA; Le-Moigne-Amrani A; de Lemos JA; Nessel CC; Harrington RA; Ferguson JJ; Braunwald E; Califf RM
JAMA; 2004 Jul; 292(1):89-96. PubMed ID: 15238596
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial.
Assadian A; Knöbl P; Hübl W; Senekowitsch C; Klingler A; Pfaffelmeyer N; Hagmüller GW
J Vasc Surg; 2008 Mar; 47(3):537-42. PubMed ID: 18234466
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Primary Thromboprophylaxis in Children with Cancer: A Systematic Review of the Literature and Network Meta-Analysis.
Pelland-Marcotte MC; Tole S; Pechlivanoglou P; Brandão LR
Thromb Haemost; 2019 Dec; 119(12):2034-2042. PubMed ID: 31600808
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison.
Sherman DG; Albers GW; Bladin C; Fieschi C; Gabbai AA; Kase CS; O'Riordan W; Pineo GF;
Lancet; 2007 Apr; 369(9570):1347-1355. PubMed ID: 17448820
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy.
Hansen JB; Sandset PM
Thromb Res; 1998 Aug; 91(4):177-81. PubMed ID: 9736420
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study.
Tuckuviene R; Ranta S; Albertsen BK; Andersson NG; Bendtsen MD; Frisk T; Gunnes MW; Helgestad J; Heyman MM; Jonsson OG; Mäkipernaa A; Pruunsild K; Tedgård U; Trakymiene SS; Ruud E
J Thromb Haemost; 2016 Mar; 14(3):485-94. PubMed ID: 26707629
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity.
Morris TA; Jacobson A; Marsh JJ; Lane JR
Thromb Res; 2005; 115(1-2):45-51. PubMed ID: 15567452
[TBL] [Abstract][Full Text] [Related]
15. Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin.
Spinal Cord Injury Thromboprophylaxis Investigators
J Trauma; 2003 Jun; 54(6):1116-24; discussion 1125-6. PubMed ID: 12813332
[TBL] [Abstract][Full Text] [Related]
16. Signs of thrombin generation in pediatric cardiac catheterization with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover.
Roschitz B; Beitzke A; Gamillscheg A; Sudi K; Koestenberger M; Leschnik B; Muntean W
Thromb Res; 2003; 111(6):335-41. PubMed ID: 14698650
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia.
Elhasid R; Lanir N; Sharon R; Weyl Ben Arush M; Levin C; Postovsky S; Ben Barak A; Brenner B
Blood Coagul Fibrinolysis; 2001 Jul; 12(5):367-70. PubMed ID: 11505079
[TBL] [Abstract][Full Text] [Related]
18. Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.
Wellington K; McClellan K; Jarvis B
Drugs; 2001; 61(8):1185-209. PubMed ID: 11465877
[TBL] [Abstract][Full Text] [Related]
19. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
van Den Belt AG; Prins MH; Lensing AW; Castro AA; Clark OA; Atallah AN; Burihan E
Cochrane Database Syst Rev; 2000; (2):CD001100. PubMed ID: 10796593
[TBL] [Abstract][Full Text] [Related]
20. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
